Literature DB >> 20703821

Renal cell carcinoma: ten years of significant advances.

Olivier Rixe, Brian Rini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20703821     DOI： 10.1007/s11523-010-0150-9

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  7 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Development of personalized tumor biomarkers using massively parallel sequencing.

Authors:  Rebecca J Leary; Isaac Kinde; Frank Diehl; Kerstin Schmidt; Chris Clouser; Cisilya Duncan; Alena Antipova; Clarence Lee; Kevin McKernan; Francisco M De La Vega; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz; Victor E Velculescu
Journal:  Sci Transl Med       Date:  2010-02-24       Impact factor: 17.956

3.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

Review 4.  Immunotherapy for renal cell cancer.

Authors:  James C Yang; Richard Childs
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

5.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

Review 6.  Renal cell carcinoma.

Authors:  Brian I Rini; Steven C Campbell; Bernard Escudier
Journal:  Lancet       Date:  2009-03-05       Impact factor: 79.321

7.  Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors:  James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 Nov-Dec       Impact factor: 4.456
  7 in total
  3 in total

1.  Incidence and prognostic significance of second primary cancers in renal cell carcinoma.

Authors:  Subhankar Chakraborty; Stefano R Tarantolo; Surinder K Batra; Ralph J Hauke
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

2.  Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor.

Authors:  Gilda Gali Hillman; Vinita Singh-Gupta; Areen K Al-Bashir; Christopher K Yunker; Michael C Joiner; Fazlul H Sarkar; Judith Abrams; E Mark Haacke
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

3.  Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study.

Authors:  Jae Young Joung; Whi-An Kwon; Jiwon Lim; Chang-Mo Oh; Kyu-Won Jung; Sung Han Kim; Ho Kyung Seo; Weon Seo Park; Jinsoo Chung; Kang Hyun Lee; Young-Joo Won
Journal:  Cancer Res Treat       Date:  2017-04-19       Impact factor: 4.679
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.